Treatment for Patients with Adenocarcinoma of Uterine Cervix


Authors

Regimen

Response rate (%)

Squamous cell carcinoma

Cai HB

CDDP+5-FU

85

Kigawa J

CDDP+BLM

80

Sugiyama T

CDDP+CPT-11

78

Chen H

CDDP+MMC+5-FU

77

Yamaguchi S

NDP+CPT-11

76

Non squamous cell carcinoma

Nagao S

DTX+CBDCA

69

Saito T

CDDP+ADM+MMC

67

Zanetta G

CDDP+EPI

67

Aoki Y

CDDP+5-FU

64

Iwasaka T

MMC+VP-16+CDDP

55


CDDP Cisplatin, 5-FU 5-fluorouracil, BLM Bleomycin, CPT-11 Irinotecan hydrochloride hydrate, MMC Mytomycin C, NDP Nedaplatin, DTX Docetaxel hydrate, CBDCA Carboplatin, ADM Doxorubicin hydrochloride, EPI Epirubicin hydrochloride, VP-16 Etoposide



Pelvic lymphnode involvement is the strongest prognostic factor in patients with cervical cancer [34, 35]. It is unknown whether patients with AC had more frequent pelvic lymphnode involvement than those with SCC. Based on our large retrospective study of 820 stage IB- IIB patients, including 280 patients with AC and 540 patients with SCC, patients with AC who had pelvic lymphnode involvement showed significantly worse outcome than those with SCC (5-years overall survival: 46.4 % vs. 72.3 %, p = 0.0005), whereas there was no difference by histological type in patients without pelvic lymphnode involvement (5-years overall survival: 91.2 % vs. 93.9 %, p = 0.4464) [36].



45.4 Adjuvant Treatment After Radical Hysterectomy


Radio-sensitivity may be also important in the treatment of patients with pathologic risk factors after radical hysterectomy. Our retrospective analysis revealed that patients with AC recurred more frequently within radiation field, such as pelvic cavity, vaginal stump, compared to those with SCC in patients receiving adjuvant radiotherapy after radical hysterectomy (24.6 % vs. 10.5 %, p = 0.0022) [36]. Peters et al. reported the randomized study on chemo-radiation versus radiation alone for pathological high-risk patients with stage IA2, IB and IIA cervical cancer [37]. Chemo-radiation was scheduled two cycles of concurrent CDDP and 5-fluorouracil and two additional cycles given after radiation. A subset analysis by histology revealed there were no significant difference in local and distant recurrence rate and outcome between AC and SCC in chemo-radiation group, whereas patients with AC showed significantly worse outcome and higher local/distant recurrence rate in radiation alone group. Our largest retrospective study also suggested that patients with AC predominantly disseminates hematogenously, whereas patients with SCC perhaps does so lymphatically [38]. Consequently, new adjuvant therapeutic strategy is necessary for pathological high-risk, especially with pelvic lymphnode involvement, patients with AC after radical hysterectomy.


45.5 Gastric-Type Mucinous Adenocarcinoma


Gastric-type mucinous adenocarcinoma (GMA), a subset of mucinous adenocarcinoma of the uterine cervix, is recently described clinicopathologic entity characterized by poor outcome and no implication of high risk HPV [3941]. To determine underlying cause of the worse prognosis for GMA, we evaluated the chemosensitivity of GMA, which were diagnosed by central pathological review of cases enrolled in our phase II study of neoadjuvant chemotherapy with docetaxel and carboplatin for stage IB2 to IIB patients with non-SCC as accompaniment study [42]. Our study revealed that patients with GMA showed significant lower response rate than those with usual-type endocervical adenocarcinoma (UAE) (46.2 % vs. 85.0 %, p = 0.018), suggesting that GMA was distinguished from UEA by chemoresistance.


45.6 In Conclusion


While majority of current management guidelines do not take histology into consideration, we should recognize that non-SCC, including AC and ASC, might be distinct from SCC, and provide an opportunity for improving outcomes for patients with non-SCC through the development of histology-specific interventions.


References



1.

Smith HO, Tiffany MF, Qualls CR, Key CR (2000) The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the United States – a 24-year population- based study. Gynecol Oncol 78:97–105CrossRefPubMed


2.

Galic V, Herzog TJ, Lewin SN, Neugut AI, Burke WM, Lu YS, Hershman DL, Wright JD (2012) Prognostic significance of adenocarcinoma histology in women with cervical cancer. Gynecol Oncol 125:287–291CrossRefPubMed


3.

Look KY, Brunetto VL, Clarke-Pearson DL, Averette HE, Major FJ, Alvarez RD, Homesley HD, Zaino RJ (1996) An analysis of cell type in patients with surgically staged stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol 63:304–311CrossRefPubMed


4.

Mabuchi S, Okazawa M, Matsuo K, Kawano M, Suzuki O, Miyatake T, Enomoto T, Kamiura S, Ogawa K, Kimura T (2012) Impact of histological subtype on survival of patients with surgically-treated stage IA2-IIB cervical cancer: adenocarcinoma versus squamous cell carcinoma. Gynecol Oncol 127:114–120CrossRefPubMed


5.

Irie T, Kigawa J, Minagawa Y, Itamochi H, Sato S, Akeshima R, Terakawa N (2000) Prognosis and clinicopathological characteristics of Ib-IIb adenocarcinoma of the uterine cervix in patients who have had radical hysterectomy. Eur J Surg Oncol 26:464–467CrossRefPubMed


6.

Gien LT, Beauchemin MC, Thomas G (2010) Adenocarcinoma: a unique cervical cancer. Gynecol Oncol 116:140–146CrossRefPubMed


7.

Rose PG (2012) Are the differences in treatment outcome for adenocarcinoma of the cervix different enough to change the treatment paradigm? Gynecol Oncol 125:285–286CrossRefPubMed

Only gold members can continue reading. Log In or Register to continue

Mar 25, 2016 | Posted by in INTERVENTIONAL RADIOLOGY | Comments Off on Treatment for Patients with Adenocarcinoma of Uterine Cervix
Premium Wordpress Themes by UFO Themes